Progress in Idiopathic Pulmonary Fibrosis: Strategies to Speed Detection and Slow Progression

Released On
July 17, 2018

Expires On
July 17, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Pulmonology, Internal Medicine, Radiology, Pathology, Pharmacy, Primary Care

Topic(s)
IPF

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Global Education Group. Paradigm Medical Communications, LLC, is the educational partner.

 

This activity is supported by an educational grant from Genentech, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of community-based pulmonologists. It may also be of benefit to other pulmonologists who are not affiliated with an interstitial lung disease (ILD) center, as well as radiologists, pathologists, primary care physicians, nurse practitioners, PAs, pharmacists, nurses, residents, fellows, and other clinicians involved in the treatment of patients with interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).

Program Overview

This enduring activity will provide pulmonologists and other clinicians with strategies to overcome challenges to the accurate and timely diagnosis of IPF, including the thorough evaluation and testing required; it will also answer their most pressing “who, what, when, where, why, and how” questions about antifibrotic use, to encourage the safe and effective integration of these agents into comprehensive IPF care plans as appropriate, and with consideration of patients’ needs and preferences.

Statement of Need

Idiopathic pulmonary fibrosis (IPF)—a fatal and relentlessly progressive fibrosing interstitial lung disease (ILD)—presents diagnostic challenges for pulmonologists, who must assess vague symptoms and rule out more than 100 other potential ILDs and non-ILD mimickers via scrupulous testing and multidisciplinary collaboration. Early detection has become more critical than ever, with the US Food and Drug Administration’s (FDA) first-ever approval of IPF treatments (antifibrotics) in October 2014. While these agents offer pulmonologists an unprecedented opportunity to slow IPF disease progression, data show that these clinicians, who are integral to IPF care, remain unfamiliar with many practical aspects of antifibrotic use, including when to start prescribing them.

Table of Contents

  • Introduction: Jumping Hurdles to Appropriate IPF Care
  • Evaluating the Nonspecific Symptoms of ILD: Guideline-based Strategies for Earlier Detection of IPF
  • Comprehensive Care of the IPF Patient: Therapeutic Options and Shared Decision-making
  • Q&A

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate patients with symptoms of interstitial lung disease according to guideline-based algorithms to correctly identify idiopathic pulmonary fibrosis.
  • Individualize antifibrotic therapy for appropriate patients with idiopathic pulmonary fibrosis, based on current evidence.
  • Outline evidence-based information about idiopathic pulmonary fibrosis disease course and treatment to share with patients at the time of diagnosis.

Faculty

David J. Lederer, MD, MS

Associate Professor of Medicine and Epidemiology
Division of Pulmonary, Allergy, and Critical Care Medicine
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center
New York, NY

Steering Committee

David J. Lederer, MD, MS (Chair)

Associate Professor of Medicine and Epidemiology
Division of Pulmonary, Allergy, and Critical Care Medicine
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center
New York, NY

Kevin R. Flaherty, MD, MS, FCCP

Professor of Medicine
Division of Pulmonary & Critical Care Medicine
University of Michigan Health System
Ann Arbor, MI

Mark L. Wencel, MD

Assistant Professor
Kansas University School of Medicine
Wichita, KS

Contributing Faculty

Jay S. Leb, MD

Assistant Professor of Radiology
Department of Radiology
Columbia University Medical Center
New York, NY

Julie Porcelli, MSN, RN, CNL

Program Coordinator
Division of Pulmonary, Allergy and Critical Care Medicine
Columbia University Medical Center
New York, NY

Anjali Saqi, MD, MBA

Professor
Department of Pathology & Cell Biology
Columbia University Medical Center
New York, NY

Patient Faculty

John Morthanos

Stratford, CT

Physician Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation Statement

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

PA Continuing Education

PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures of Conflicts of Interest

Global Education Group (Global) and Paradigm Medical Communications, LLC, (Paradigm) require instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global and Paradigm for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

David J. Lederer, MD, MS

  • Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc; Global Blood Therapeutics Inc.
  • Retained Consultant: FibroGen, Inc; Galapagos NV; Global Blood Therapeutics Inc.; Roche; Sanofi Genzyme; Veracyte, Inc.

The steering committee reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Kevin R. Flaherty, MD, MS, FCCP

  • Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc.
  • Retained Consultant: Boehringer Ingelheim Pharmaceuticals, Inc; Roche/Genentech, Inc.; Veracyte, Inc.

Mark L. Wencel, MD

  • Speakers Bureau: Genentech, Inc.

The contributing faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Jay S. Leb, MD

  • Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.

John Morthanos

  • Honorarium: Pulmonary Fibrosis Foundation Ambassador

Julie Porcelli, MSN, RN, CNL

  • Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.

Anjali Saqi, MD, MBA

  • Grant/Research Support: Columbia-Coulter Translational Research Partnership; FAR-ILD
  • Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.
  • Retained Consultant: Boston Scientific Corporation; Genentech, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Robert M. Byrnes: No financial relationships to disclose.
  • Lindsay Borvansky: No financial relationships to disclose.
  • Karen Kaufman: No financial relationships to disclose.
  • Andrea Funk: No financial relationships to disclose.
  • Liddy Knight: No financial relationships to disclose.

Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose

Instructions for Participation

To receive a CME certificate of participation, participants must:

  • Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pretest.
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation.

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your freeCME CME History.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Course Viewing Requirements

This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers:

For Desktops (Windows/Mac): Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface): iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Technical Support:
If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Paradigm do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Global and Paradigm activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Global or Paradigm.

Terms of Use and Privacy Policy

Disclaimer

The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Global Education Group or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Global or Paradigm. Global and Paradigm accept no liability for the content referenced in this activity.

Privacy Policy

Global and Paradigm are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/Safeguarding Personal Information

This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and User of Your Personal Information

The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Global and Paradigm to continuously improve the learning experience.

Global Education Group and Paradigm Medical Communications, LLC, do not transfer, sell, or share personal information with outside parties. Global Education Group and Paradigm will not otherwise disclose personal information unless required to in a legal process. Global and Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Information

If you have any questions or comments, please email us at contactus@paradigmmc.com.

©2018 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.